As US Food and Drug Administration (FDA) vaccine advisors prepare to consider Moderna’s COVID-19 vaccine for emergency use authorization (EUA) later this week, an agency review posted ahead of the meeting made a strong case, suggesting that a two-dose regimen was safe and 94% effective at preventing disease. The development comes as more states immunized the first people in two priority groups—health workers and nursing home residents—with the recently approved Pfizer-BioNTech vaccine and sets the stage for two vaccines to be cleared for emergency use, expanding the reach of the immunization campaign’s rollout. Both are messenger RNA (mRNA) vaccines.

 

Read more CIDRAP…